TRIPP, the Los Angeles-based startup that combines virtual and alternate realities with psychedelic imagery to boost mental wellness, has made its first acquisition – PsyAssist – as it moves deeper into psychedelic-assisted therapies, Mobihealth News reports.
While TRIPP bills itself as a digital psychedelic company, its platform didn’t actually involve the use of psychedelic drugs – until now.
TRIPP presents psychedelic visuals, target sounds and interoperations through a VR headset to help users treat substance abuse disorders, anxiety, pain and depression, and to improve their quality of life during cancer treatment.
By bringing PsyAssist into the fold, TRIPP will integrate the company’s psychedelic therapy protocols with its VR platform to support psychotherapists and patients through ketamine-assisted therapy, as well as in MDMA and psilocybin clinical trials.
